Atara Biotherapeutics, Inc.

Industry and platform

• Biopharmaceutical company focused on T-cell immunotherapy.
• Develops an off-the-shelf, allogeneic EBV-sensitized T-cell platform to create readily available cellular therapies for cancer and autoimmune diseases.
• Platform is designed for rapid delivery of pre-manufactured T-cell therapies held in inventory, with product selection informed by a patient’s immune profile.

Core product and approvals

• Tab-cel (tabelecleucel) is an allogeneic EBV-specific T-cell immunotherapy.
• Marketed in the European Union, the United Kingdom, and Switzerland under the name Ebvallo™.
• In Phase 3 development in the United States for EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) after rituximab or rituximab-plus-chemotherapy failure. Holds FDA Breakthrough Therapy Designation and orphan designations in the U.S. and EU for PTLD post-transplant.

Partnerships and commercialization

• Pierre Fabre Commercialization Agreement: exclusive, field-limited license to commercialize Ebvallo in Europe and certain emerging markets (Initial Territory), with a framework for later expansion to additional countries under amendments.
• Pierre Fabre assumed manufacturing and regulatory responsibilities over time; as of March 2025, Pierre Fabre is responsible for worldwide manufacturing of tab-cel at its cost, with remediation costs addressed under the amended agreement.
• HCRx Agreement: sale of a portion of Ebvallo royalties and milestones to fund expansion and related activities, subject to a cap (185–250% of the invested amount).
• Fujifilm manufacturing relationship (Fujifilm MSA) provided product supply; manufacturing responsibilities were subsequently transferred and assigned to Pierre Fabre.

Programs paused or wound down

• ATA3219 (allogeneic CD19 CAR T for NHL and SLE with lupus nephritis): Safe to Proceed/clinical hold history; decision in March 2025 to pause and discontinue ATA3219; wind-down nearly complete.
• ATA3431 (allogeneic dual CD19/CD20 CAR T): paused March 2025; wind-down nearly complete.
• ATA188 (MS) and EBV vaccine: rights returned to QIMR Berghofer in May 2025.
• Tab-cel multi-cohort study and other EBV-driven programs are subject to ongoing wind-down as part of strategic and manufacturing transitions.

Strategy and corporate actions

• Board initiated a review of strategic alternatives in January 2025 to maximize stockholder value. Considered options include acquisitions, mergers, asset sales, licensing, or other strategic transactions.
• The company is pursuing strategic options, potential liquidity events, or wind-down actions as warranted to maximize value.

Intellectual property

• Holds and/or licenses a broad IP portfolio tied to the EBV-T-cell platform and tab-cel technology.
• Global patent estate comprises 11 patent families with more than 180 issued patents or patent applications.
• Patent terms generally run from 2024 to 2044, subject to extensions and jurisdictional rules.

Financial and operating status (year-end 2025)

• Employees: 14 (as of December 31, 2025).
• Cash and cash equivalents: $8.5 million (as of December 31, 2025).
• For the year ended December 31, 2025, net income was $32.7 million, driven by commercialization revenue and reductions in operating expenses.
• The company has reported a history of substantial operating losses and has disclosed going-concern considerations; it plans to seek additional capital through equity, debt, or strategic transactions.
• Public float was less than $75 million as of the filing date, resulting in Form S-3 shelf-registration limitations until float exceeds $75 million.
• The company depends substantially on Pierre Fabre for development, manufacturing, and commercialization of tab-cel in the Initial Territory and, post-2025, worldwide; partner nonperformance could materially affect operations and finances.

Product development and regulatory

• Tab-cel is being developed for PTLD and other EBV-driven diseases; regulatory approvals exist in the EU, UK, and Switzerland, and U.S. development continues under a BLA pathway with ongoing regulatory interactions, including 2025–2026 FDA responses and manufacturing inspections.
• Regulatory designations include orphan status in the U.S. and EU and Breakthrough Therapy Designation in the U.S.
• Manufacturing has transitioned to Pierre Fabre; the company relies on third-party CMOs and continues to manage risks related to GMP/GTP compliance, supply continuity, and scale-up.

Business focus

• Atara concentrates on a scalable, off-the-shelf T-cell immunotherapy platform with a marketed product, Ebvallo (tab-cel), in Europe and the UK, and ongoing U.S. development for EBV+ PTLD.
• The business model emphasizes strategic partnerships and licensing while pursuing alternatives to maximize stockholder value.
• Several CAR T programs and other initiatives have been paused or wound down to focus resources on commercialization and potential future opportunities.